BrainStorm Cell Therapeutics Announces Presentations on NurOwn at 2024 Annual NEALS Meeting
BCLI Stock | USD 1.61 0.03 1.90% |
Under 54% of Brainstorm Cell's investor base is interested to short. The analysis of the overall investor sentiment regarding Brainstorm Cell Therapeutics suggests that many traders are impartial. Brainstorm Cell's investing sentiment shows overall attitude of investors towards Brainstorm Cell Therapeutics.
Brainstorm |
BrainStorm Cell Therapeutics Inc. , a leading developer of cellular therapies for neurodegenerative diseases, today announced the acceptance of two abstracts featuring NurOwn at the 2024 Annual Northeastern Amyotrophic Lateral Sclerosis Consortium Meeting, to take place October 21 - 24, in-person in Clearwater, Florida and virtually.
Read at finance.yahoo.com
Brainstorm Cell Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Brainstorm Cell can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Brainstorm Cell Fundamental Analysis
We analyze Brainstorm Cell's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brainstorm Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brainstorm Cell based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Brainstorm Cell is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Brainstorm Cell Ther Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Brainstorm Cell stock to make a market-neutral strategy. Peer analysis of Brainstorm Cell could also be used in its relative valuation, which is a method of valuing Brainstorm Cell by comparing valuation metrics with similar companies.
Peers
Brainstorm Cell Related Equities
INZY | Inozyme Pharma | 9.56 | ||||
TERN | Terns Pharmaceuticals | 5.17 | ||||
ANTX | AN2 Therapeutics | 4.64 | ||||
PLX | Protalix Biotherapeutics | 3.98 | ||||
CUE | Cue Biopharma | 3.64 | ||||
CCCC | C4 Therapeutics | 2.86 | ||||
CKPT | Checkpoint Therapeutics | 2.04 | ||||
CNTB | Connect Biopharma | 1.79 | ||||
MREO | Mereo BioPharma | 1.58 | ||||
HCWB | HCW Biologics | 0.75 | ||||
HOWL | Werewolf Therapeutics | 0.54 | ||||
XFOR | X4 Pharmaceuticals | 0.45 | ||||
PASG | Passage Bio | 0.32 | ||||
CRVS | Corvus Pharmaceuticals | 0.25 | ||||
GRI | GRI Bio | 0.65 | ||||
CELC | Celcuity LLC | 0.70 | ||||
DAWN | Day One | 1.86 | ||||
ALDX | Aldeyra | 2.08 | ||||
TRVI | Trevi Therapeutics | 2.24 | ||||
GBIO | Generation Bio | 2.34 | ||||
EWTX | Edgewise Therapeutics | 2.58 | ||||
BCAB | Bioatla | 3.73 |
Complementary Tools for Brainstorm Stock analysis
When running Brainstorm Cell's price analysis, check to measure Brainstorm Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brainstorm Cell is operating at the current time. Most of Brainstorm Cell's value examination focuses on studying past and present price action to predict the probability of Brainstorm Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brainstorm Cell's price. Additionally, you may evaluate how the addition of Brainstorm Cell to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |